Difference between revisions of "WSI22-127-Case-2"

From MGH Learn Pathology
(Added status template)
 
(2 intermediate revisions by one other user not shown)
Line 34: Line 34:
 
|subject=Z0FBQUFBQmpJNXRsYXVNcHVmd2RDOWZEaFl6akFReEx1UTdfTnJ4NDJ5aUtFZ3VaRkRack9iRVRfVnRaV0syUXdjVXByUmoyY0FwWGJGZnV2cFE3cXZRNUstMy10blBDS0E9PQ
 
|subject=Z0FBQUFBQmpJNXRsYXVNcHVmd2RDOWZEaFl6akFReEx1UTdfTnJ4NDJ5aUtFZ3VaRkRack9iRVRfVnRaV0syUXdjVXByUmoyY0FwWGJGZnV2cFE3cXZRNUstMy10blBDS0E9PQ
 
|reasonCode=BRAF
 
|reasonCode=BRAF
|view=show
+
|view=hide
 
|modality=mrxs
 
|modality=mrxs
 
}}
 
}}
Line 46: Line 46:
 
|view=show
 
|view=show
 
|modality=mrxs
 
|modality=mrxs
 +
}}
 +
{{status
 +
|status=active
 +
|requester=Af400
 +
|authoredOn=September 15, 2022 09:34:48 PM
 
}}
 
}}

Latest revision as of 14:30, December 9, 2024

WSI22-127-Case-2
30s female with thyroid mass and enlarged bilateral lymph nodes.
Papillary thyroid carcinoma, diffuse sclerosing variant. Follow-up molecular: CCDC6(e1)::RET(e12) fusion.
October 26, 2022 1:15:00 AM